NCT01597219 - Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

January 31, 2024

Study Completion Date

January 31, 2024

Conditions

Hodgkin's LymphomaNon-Hodgkin's LymphomaAcute Myeloid LeukaemiaAcute Lymphoblastic LeukaemiaMyelodysplastic SyndromeChronic Myeloid LeukaemiaChronic Lymphocytic LeukaemiaAcquired Bone Marrow Failure SyndromesOther Haematological Malignancies; Unrelated HSCT Indicated

Interventions

PROCEDURE

Reduced intensity haplodentical stem cell transplant

Fludarabine 30mg/m2 IV days -6 to -2 Cyclophosphamide 14.5 mg/kg IV days -6 and -5 Total body irradiation 2Gy day -1 Stem cell transplant: day 0 Cyclophosphamide 50mg/kg days +3 \& +4

PROCEDURE

Myeloablative haploidentical stem cell transplant

Total body irradiation 12Gy in 8 fractions days -9 to -6 Donor lymphocyte infusion day -6 Cyclophosphamide 60mg/kg IV days -3 \& -2 Stem cell transplant day 0

Trial Locations (12)

Unknown

Birmingham Heartlands, Birmingham

Bristol Royal Infirmary, Bristol

Addenbrooke's Hospital, Cambridge

Beatson Hospital, Glasgow

St James' University Hospital, Leeds

Royal Liverpool Hospital, Liverpool

King's College Hospital, London

St Bartholomew's Hospital, London

University College Hospital, London

Manchester Royal Infirmary, Manchester

Freeman Hospital, Newcastle

Royal Hallamshire, Sheffield & Weston Park, Sheffield

All Listed Sponsors

collaborator

Bloodwise

OTHER

lead

University College, London

OTHER